Dendritic cells as vectors for immunotherapy of cancer

Sophie Paczesny, Hideki Ueno, Joseph Fay, Jacques Banchereau, A. Karolina Palucka

Research output: Contribution to journalReview article

47 Scopus citations

Abstract

Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti-tumor immunity. The immunogenicity of antigens delivered on DCs has now been demonstrated in cancer patients and some clinical responses without any significant toxicity have been observed. Nevertheless, many parameters of DC vaccination need to be established including: (1) the type of DCs, their maturation stage and stimuli; (2) the quality and the breadth of induced immune responses; (3) host-related factors, such as the extent of metastatic disease and myeloablation; and (4) efficacy as measured by the clinical outcome.

Original languageEnglish (US)
Pages (from-to)439-447
Number of pages9
JournalSeminars in Cancer Biology
Volume13
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Keywords

  • Dendritic cells
  • Immunotherapy
  • Tumor immunology
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Dendritic cells as vectors for immunotherapy of cancer'. Together they form a unique fingerprint.

  • Cite this

    Paczesny, S., Ueno, H., Fay, J., Banchereau, J., & Palucka, A. K. (2003). Dendritic cells as vectors for immunotherapy of cancer. Seminars in Cancer Biology, 13(6), 439-447. https://doi.org/10.1016/j.semcancer.2003.09.008